After applying inclusion and exclusion criteria and propensity matching, we analyzed 24,078 patients with T2DM, with 12,039 in the canagliflozin group and 12,039 in the selective SGLT2 inhibitor group (Table 1). This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.